ENCAPSULATED N-ACETYLMANNOSAMINE OR N-ACETYLNEURAMINIC ACID TO INCREASE SIALYLATION
A method for treating a disorder characterized by hyposialylation in a subject that includes administering to the subject an effective amount of (i) a composition comprising N-acetylmannosamine, or a derivative thereof, encapsulated within a liposome, or (ii) a composition comprising N-acetylneuraminic acid, or a derivative thereof, encapsulated within a liposome, wherein the liposome comprises 1,2-dioleoyl-3-trimethylammonium-propane and cholesterol.
1 . A method for treating a disorder characterized by hyposialylation in a subject comprising administering to the subject an effective amount of (i) a composition comprising N-acetylmannosamine, or a derivative thereof, encapsulated within a liposome, or (ii) a composition comprising N-acetylneuraminic acid, or a derivative thereof, encapsulated within a liposome, wherein the liposome comprises 1,2-dioleoyl-3-trimethylammonium-propane and cholesterol.
2 . A method for increasing sialic acid in a subject in need thereof comprising administering to the subject an effective amount of (i) a composition comprising N-acetylmannosamine, or a derivative thereof, encapsulated within a liposome, or (ii) a composition comprising N-acetylneuraminic acid, or a derivative thereof, encapsulated within a liposome, wherein the liposome comprises 1,2-dioleoyl-3-trimethylammonium-propane and cholesterol, to thereby increase sialic acid levels in the subject.
3 . A method for treating a disorder characterized by hyposialylation in a subject comprising:
identifying a subject in need of treatment for hyposialylation; and
administering to the subject an effective amount of (i) a composition comprising N-acetylmannosamine, or a derivative thereof, encapsulated within a liposome, or (ii) a composition comprising N-acetylneuraminic acid, or a derivative thereof, encapsulated within a liposome, wherein the liposome comprises 1,2-dioleoyl-3-trimethylammonium-propane and cholesterol.
4 . The method of claim 1 , wherein the composition (i) or the composition (ii) is administered to the subject intravenously.
5 . The method of claim 1 , wherein composition (i) is administered to the subject.
6 . The method of claim 1 , wherein composition (ii) is administered to the subject.
7 . The method of claim 1 , wherein the disorder is myopathy, a kidney condition, a hyposialylated cancer, or a neurodegenerative disease.
8 . The method of claim 7 wherein the myopathy is hereditary inclusion body myopathy.
9 . The method of claim 7 wherein the myopathy is distal myopathy with rimmed vacuoles.
10 . The method of claim 1 , wherein composition (i) comprises N-acetylmannosamine.
11 . The method of claim 1 , wherein composition (ii) comprises N-acetylneuraminic acid.
12 . The method of claim 2 , wherein the composition (i) or the composition (ii) is administered to the subject intravenously.
13 . The method of claim 2 , wherein composition (i) is administered to the subject.
14 . The method of claim 2 , wherein composition (ii) is administered to the subject.
15 . The method of claim 2 , wherein composition (i) comprises N-acetylmannosamine.
16 . The method of claim 2 , wherein composition (ii) comprises N-acetylneuraminic acid.